Phase 3 Lupus Trial, Recruiting NCT06904729 Sponsor: Guangzhou Women and Children's Medical Center Condition: Lupus
Back to Lupus

Phase 3 Lupus Trial, Recruiting

NCT06904729
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 6 and 18 years old (including those who are exactly 6 or 18)
  • You have been diagnosed with Systemic Lupus Erythematosus (SLE) based on recognised 2019 international guidelines
  • You have been diagnosed with an active, serious form of lupus affecting the kidneys (called lupus nephritis, Class III or IV), confirmed by a kidney biopsy taken within the last 6 months
  • Your lupus disease activity score is at a certain level of severity (SLEDAI-2000 score of 8 or higher) (confirm with trial site)
  • Your lupus nephritis has not responded well to treatment — meaning you have tried two or more immune-suppressing medications for more than 6 months without the disease going into remission, or it came back after remission, and you still have protein in your urine
  • A blood test has shown that a certain type of immune cell called CD19 B cells is present in your blood
  • You have suitable veins and no medical reason preventing collection of your blood cells
  • You and your parent or guardian are willing to give written consent and take part voluntarily
  • Your blood cell counts meet certain minimum levels (for example, your white blood cells, infection-fighting cells, and haemoglobin are above set thresholds) (confirm with trial site)
  • Your liver is functioning within acceptable limits based on blood tests (confirm with trial site)
  • Your kidneys are still functioning at a certain minimum level, as measured by a calculation called eGFR (at least 30 ml/min/1.73m²)
  • Your blood clotting results are within acceptable limits (confirm with trial site)
  • Your heart is stable
  • A specific lupus-related antibody called ANA is present at a level of 1:80 or higher in your blood
  • Your general physical ability is rated between 0 and 2 on a standard scale (meaning you are able to carry out everyday activities, possibly with some limitations) (confirm with trial site)

Who may not be able to join:

  • You have previously had a kidney transplant
  • You have a history of serious allergic reactions to medications
  • You currently have an active infection (fungal, bacterial, viral, or other) that is not under control or needs treatment
  • You have serious problems with your heart, liver, lungs, or blood clotting
  • You were born with a condition that means your body cannot produce enough antibodies (congenital immunoglobulin deficiency)
  • You have active Hepatitis B, active Hepatitis C, HIV, or syphilis
  • You have been diagnosed with cancer at any point in the last five years
  • You have a serious disease of the brain or nervous system, a serious mental illness, or significant problems with thinking or memory
  • You have taken part in another clinical trial within the past 3 months
  • You have previously received a type of treatment called CAR-T cell therapy
  • The trial doctors decide there is another reason that makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86+020-81330569

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Guangzhou Women and Children's Medical Center
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
30 April 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Number of participants with CAR-T cells treatment-related adverse events(AE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov